PROS1 and COVID-19: Approaches to address COVID‐19 start to fade away from drug repurposing and the S protein to more classic rational strategies to target functional viral proteins, as demonstrated by the main protease (Mpro) inhibitor nirmatrelvir, the first oral anti‐COVID‐19 drug approved by the FDA.